Drug Profile
ATI 355
Alternative Names: Anti NOGO-A mAb; Anti-Nogo antibody; ATI-355; NG 101; NG-101 - NovartisLatest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Monoclonal antibodies
- Mechanism of Action Nerve growth factor stimulants; Nogo protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Spinal cord injuries
Most Recent Events
- 02 Feb 2023 Novartis and University of Zurich complete the phase II NISCI trial in Spinal cord injuries (In adults, In the elderly) in Czech Republic, Spain, Germany and Switzerland (Intrathecal) (EudraCT2016-001227-31), (NCT03935321)
- 29 Nov 2022 ATI 355 is still in phase II trials for Spinal cord injuries (In adults, In the elderly) in Germany, Switzerland (Intrathecal) (NCT03935321)
- 19 Jun 2019 Phase-II clinical trials in Spinal cord injuries (In adults, In the elderly) in Germany (Intrathecal, Injection) (NCT03935321)